UniSuper Management Pty Ltd Lowers Position in Zoetis Inc. (NYSE:ZTS)

UniSuper Management Pty Ltd decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 68.7% in the 4th quarter, Holdings Channel reports. The firm owned 31,176 shares of the company’s stock after selling 68,272 shares during the period. UniSuper Management Pty Ltd’s holdings in Zoetis were worth $5,080,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Mission Wealth Management LP grew its stake in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares in the last quarter. VeraBank N.A. grew its position in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares in the last quarter. HUB Investment Partners LLC increased its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after acquiring an additional 62 shares during the last quarter. Procyon Advisors LLC raised its position in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its stake in Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZTS has been the topic of several recent research reports. Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Stifel Nicolaus reduced their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Buying and Selling at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $163.03 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market cap of $73.00 billion, a price-to-earnings ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company has a 50-day moving average price of $166.40 and a 200-day moving average price of $174.67.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.